NCT02216630View on ClinicalTrials.gov

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Adipose Derived Stem Cell (ADSC) Therapy

Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.

Trial Locations (5)

10001

New York, New York

33330

Melvin Propis M.D., Davie

60061

Chicago, Chicago

75251

Dallas, Dallas

89030

Las Vegas, Las Vegas

All Listed Sponsors
lead

Kimera Society Inc

INDUSTRY

NCT02216630 - Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter